User profiles for "author:Peter van der Meer"
peter van der meerCardiologist, University Medical Center Groningen Verified email at umcg.nl Cited by 53393 |
2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery: Developed by the task force for cardiovascular …
S Halvorsen, J Mehilli, S Cassese, TS Hall… - European heart …, 2022 - academic.oup.com
Off-label use of medication may be presented in these guidelines if a sufficient level of
evidence shows that it can be considered medically appropriate to a given condition and if …
evidence shows that it can be considered medically appropriate to a given condition and if …
Anemia and mortality in heart failure patients: a systematic review and meta-analysis
HF Groenveld, JL Januzzi, K Damman… - Journal of the American …, 2008 - jacc.org
Objectives: The aim of this study was to assess the effect of anemia on mortality in chronic
heart failure (CHF). Background: Anemia is frequently observed in patients with CHF, and …
heart failure (CHF). Background: Anemia is frequently observed in patients with CHF, and …
A systematic review and network meta-analysis of pharmacological treatment of heart failure with reduced ejection fraction
J Tromp, W Ouwerkerk, DJ van Veldhuisen, HL Hillege… - Heart Failure, 2022 - jacc.org
Objectives This study sought to estimate and compare the aggregate treatment benefit of
pharmacological therapy for heart failure (HF) with reduced ejection fraction. Background …
pharmacological therapy for heart failure (HF) with reduced ejection fraction. Background …
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic …
AR Lyon, T López-Fernández, LS Couch… - European Heart …, 2022 - academic.oup.com
ESC Guidelines e341 (1) the specific situation of the patient. In this respect, it is specified
that, unless otherwise provided for by national regulations, offlabel use of medication should …
that, unless otherwise provided for by national regulations, offlabel use of medication should …
Semaglutide in patients with heart failure with preserved ejection fraction and obesity
MN Kosiborod, SZ Abildstrøm, BA Borlaug… - … England Journal of …, 2023 - Mass Medical Soc
Background Heart failure with preserved ejection fraction is increasing in prevalence and is
associated with a high symptom burden and functional impairment, especially in persons …
associated with a high symptom burden and functional impairment, especially in persons …
Phase 1 trial of antibody NI006 for depletion of cardiac transthyretin amyloid
P Garcia-Pavia, F Aus dem Siepen… - … England Journal of …, 2023 - Mass Medical Soc
Background Transthyretin amyloid (ATTR) cardiomyopathy is a progressive and fatal
disease caused by misfolded transthyretin. Despite advances in slowing disease …
disease caused by misfolded transthyretin. Despite advances in slowing disease …
[HTML][HTML] Iron deficiency in chronic heart failure: an international pooled analysis
IJT Klip, J Comin-Colet, AA Voors, P Ponikowski… - American heart …, 2013 - Elsevier
BACKGROUND: Iron deficiency (ID) is an emerging problem in patients with chronic heart
failure (HF) and can be a potential therapeutic target. However, not much is known about the …
failure (HF) and can be a potential therapeutic target. However, not much is known about the …
Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction
RA de Boer, DJA Lok, T Jaarsma… - Annals of …, 2011 - Taylor & Francis
Aims. Galectin-3 is an emerging biomarker which has been studied in relatively small heart
failure (HF) cohorts with predominantly systolic HF. We studied the prognostic value of base …
failure (HF) cohorts with predominantly systolic HF. We studied the prognostic value of base …
[HTML][HTML] Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study
DJA Lok, P Van Der Meer, PWBA de la Porte… - Clinical research in …, 2010 - Springer
Aims Biomarkers are increasingly being used in the management of patients with chronic
heart failure (HF). Galectin-3 is a recently developed biomarker associated with fibrosis and …
heart failure (HF). Galectin-3 is a recently developed biomarker associated with fibrosis and …
Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial
P Ponikowski, BA Kirwan, SD Anker, T McDonagh… - The Lancet, 2020 - thelancet.com
Background Intravenous ferric carboxymaltose has been shown to improve symptoms and
quality of life in patients with chronic heart failure and iron deficiency. We aimed to evaluate …
quality of life in patients with chronic heart failure and iron deficiency. We aimed to evaluate …